Imaging caspase-3 activation as a marker of apoptosis-targeted treatment response in cancer.

ABSTRACT:

Purpose

We tested whether positron emission tomography (PET) with the caspase-3-targeted isatin analog [(18)F]WC-4-116 could image caspase-3 activation in response to an apoptosis-inducing anticancer therapy.

Procedures

[(18)F]WC-4-116 uptake was determined in etoposide-treated EL4 cells. Biodistribution studies with [(18)F]WC-4-116 and [(18)F]ICMT-18, a non-caspase-3-targeted tracer, as well as [(18)F]WC-4-116 microPET imaging assessed responses in Colo205 tumor-bearing mice treated with death receptor 5 (DR5)-targeted agonist antibodies. Immunohistochemical staining and enzyme assays confirmed caspase-3 activation. Two-way analysis of variance or Student's t test assessed for treatment-related changes in tracer uptake.

Results

[(18)F]WC-4-116 increased 8 ± 2 fold in

SUBMITTER: Chen DL 

PROVIDER: S-EPMC4874215 | biostudies-literature | 2015 Jun

REPOSITORIES: biostudies-literature